



## PRODUCT ROLLOUT

### First Generation: waveforce ONE

FREmedica, in 2017 sold the first 200 waveforce ONE emitters. The product was a plug and play version with no upgrade or upload features and was available for practitioners and chronic Lyme patients to purchase online.

### Second Generation: WAVE 1

FREmedica has completed the incremental development of the WAVE 1. This device is hardware ready to support the future business model of subscription delivered frequencies which support the immune system in dealing with chronic Lyme disease. The company began with 100 prototype WAVE 1s in early 2018, and experienced success, leading to an additional 300 units being delivered in 2018. In 2019, we soft launched and sales of 1070 devices. We are projecting sales of 2000 devices for 2021.

### Market Size

476,000 cases of Lyme disease in the USA are projected each year . FREmedica's first market is North America where there are approximately 3,948,000 people with Lyme disease . Due to difficulty with diagnosis, many sources estimate that the actual number of people suffering from chronic Lyme is likely much higher in North America. FREmedica's second market will be Europe where the number of cases in Europe has increased steadily, with more than 360,000 cases reported over the last two decades diagnosed every year, and the numbers continue to rise worldwide as the black legged tick population spreads.